Targeted therapies in gastric cancer—the dawn of a new era

Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(13)61719-5 .

Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).

Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).

Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at the histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49 (1965).

Tan, I. B. et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141, 476–485 (2011).

Shah, M. A. et al. Molecular classification of gastric cancer: a new paradigm. Clin. Cancer Res. 17, 2693–2701 (2011).

Yamada, Y. et al. Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912 [abstract 4535]. J.Clin. Oncol. 27 (Suppl.), a4535 (2009).

Ohtsu, A. et al. Bevacizumab in combination with chemohterapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968–3976 (2011).

Van Cutsem, E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119–2127 (2012).